SynthesisBMC cardiovascular disorders2026

Renal and cardiovascular outcomes and safety of SGLT2 inhibitors in patients aged ≥ 65 years with non-dialysis chronic kidney disease: a systematic review and meta-analysis of subgroup-level estimates derived from randomized trials.

Ziyang Bao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.